Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01417312

Enrollment

Registered

2011-08-16

Start date

2011-07-31

Completion date

2013-01-31

Last updated

2021-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Relapsing-Remitting

Keywords

Multiple sclerosis, Green tea extract, Metabolism

Brief summary

This study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (EGCG), in multiple sclerosis patients.

Interventions

DIETARY_SUPPLEMENTCapsules with 160 mg Teavigo (at least 94% EGCG)

Daily intake of 600 mg EGCG for 3 months

DIETARY_SUPPLEMENTPlacebo

Daily intake of placebo capsules for 3 months

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients with relapsing-remitting multiple sclerosis * stable treatment with glatiramer acetate at least 6 months prior to inclusion * Expanded disability status scale \< 4.5 * Normal weight, overweight

Exclusion criteria

* Primary or secondary progressive forms of multiple sclerosis * Clinically relevant heart, lung, liver, kidney diseases * Habitual caffeine intake over 300 mg per day * Habitual consumption of green tea * Alcohol or drug abuse

Design outcomes

Primary

Measure	Time frame
Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo	Three months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026